Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Total Current Liabilities
All obligations due within one year.
Monopar Therapeutics Inc.NASDAQ: MNPR
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 64.7% from a year ago
Total current liabilities stood at $2.46M at the end of Q1 FY2026, up 64.7% from a year earlier and down 10.1% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Total current liabilities amounted to 1.8% of total assets at the end of Q1 FY2026, down 0.9 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +64.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.74M USD
- Year-over-year change
- -47.9%
- 4-year CAGR
- +14.7%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.74M | -47.9% |
| FY2024 | 2024-12-31 | 5.25M | +199.0% |
| FY2023 | 2023-12-31 | 1.76M | -43.8% |
| FY2022 | 2022-12-31 | 3.13M | +98.0% |
| FY2021 | 2021-12-31 | 1.58M | — |
Total Current Liabilities vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +64.7% is the 3rd highest of 11, against a peer median of +11.2%.
- Total current liabilities amounts to 1.8% of total assets for MNPR, versus a peer median of 12.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $161.46M USD | +284.0% | -23.8% | 13.7% | |
| Mar 2026 | $95.94M USD | +73.0% | -3.9% | 44.0% | |
| Jun 2026 | $81.87M USD | -14.8% | +14.5% | 11.3% | |
| Mar 2026 | $67.63M USD | +17.0% | -5.0% | 23.2% | |
| Mar 2026 | $48.89M USD | -15.2% | +2.2% | 7.5% | |
| Sep 2026 | $40.97M USD | +30.3% | +83.1% | 8.1% | |
| Dec 2025 | €36.63M EUR | +11.1% | -3.9% | 58.4% | |
| Mar 2026 | $20.18M USD | +7.7% | -4.7% | 11.3% | |
| Mar 2026 | $10.28M USD | -31.0% | -4.8% | 5.0% | |
| Jun 2026 | $9.26M USD | +11.4% | -9.2% | 23.1% | |
| Mar 2026 | $2.46M USD | +64.7% | -4.4% | 1.8% | |
| Peer median (excluding MNPR) | — | +11.2% | -4.3% | 12.5% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.